💸 The Tape

Glass House Brands is in the middle of the most uncomfortable kind of growth story — the kind where you're investing heavily in scale while the current market punishes you for it. The Q1 2026 results are objectively rough. But the thesis behind them hasn't changed, and management is betting that the payoff is coming.

The California-focused cannabis producer reported Q1 revenue of $40.5 million, down 9.6% from $44.8 million in Q1 2025 but up 4.1% sequentially from Q4's $38.9 million — and ahead of the company's own $39 million guidance. The top line beat expectations, which is about where the good news ends on the income statement. Gross margin compressed to 25%, down dramatically from 45% a year ago and 34% last quarter. Adjusted EBITDA was negative $4.2 million, compared to positive $4.4 million in Q1 2025. Operating cash flow was negative $11.8 million.

Those numbers hurt. But they need context.

The Cost Transition

The margin compression is driven by a specific and transitory dynamic: cost of production per equivalent dry pound spiked to $175, up from $108 a year ago and $129 in Q4. That increase reflects the company's aggressive buildout of Greenhouse 2, which was accelerated and completed during the quarter to prepare for rescheduling-driven opportunities. When you bring significant new cultivation capacity online, the costs hit before the revenue does — and Q1 caught Glass House in that awkward middle period.

Management isn't hiding from it. CEO Kyle Kazan acknowledged the results reflect "a build-up of cultivation scale and transitory inflated cost of production" and committed to making changes to "ensure our future performance returns to the standards that we demand of ourselves."

The company reiterated its full-year guidance: approximately one million pounds of cannabis biomass production (a company record), an average selling price in the mid-$180s per pound, and a path to achieving its $95 per pound production cost target on a quarterly basis in the second half of 2026. If Glass House hits that cost target while selling at $185, the margin math changes dramatically from where it sits today.

Production Held Strong

Despite the cost issues, the production engine performed. Biomass output was 151,531 pounds, ahead of the guided 138,000 pounds and roughly in line with the prior year's 152,568 pounds. The company can grow cannabis at enormous scale — the challenge right now is doing it at the cost profile that makes the business model work.

Average selling price came in at $171 per pound, above the guided $167 but well below last year's $193. California's wholesale pricing environment remains punishing, and Glass House continues to operate in what Kazan described as "challenged California pricing conditions." The company's long-term bet has always been that its greenhouse-based model — which avoids the massive energy costs of indoor cultivation and doesn't rely on third-party water supply — provides structural cost advantages that will separate it from peers over time. Q1 tested that thesis more than most quarters.

Segment Breakdown

The wholesale biomass segment generated $24 million in revenue, accounting for 59% of the total. Retail contributed $11.9 million with a 50% gross margin — up from 47% in Q4 — providing a higher-margin counterbalance to the wholesale challenges. Wholesale CPG added $4.6 million, up 7% sequentially.

The retail segment's margin improvement is notable and suggests that Glass House's dispensary operations are performing well independently of the wholesale headwinds. As the company's California retail joint venture with Vireo Growth comes together — combining 23 dispensaries and the Eaze delivery platform — the retail contribution should become an increasingly important piece of the revenue and margin mix.

The Rescheduling Opportunity

Kazan framed the Schedule III rescheduling of medical cannabis as "a landmark event" with vast implications for Glass House. The company has already submitted DEA registration applications for its medical operations, permitting it to immediately operate under the new Schedule III framework.

But the bigger opportunity Kazan highlighted goes beyond 280E tax relief. He pointed to the potential for interstate commerce and European export — two developments that would "meaningfully increase our addressable market size and unlock greater profit and cash flow generation driven by more favorable pricing dynamics."

That's the strategic logic that underpins Glass House's entire expansion push. If cannabis can eventually move across state lines or internationally, a company producing one million pounds annually at sub-$100 cost per pound from California greenhouses would have an extraordinary competitive position. The current California pricing environment — where wholesale prices are among the lowest in the country — becomes an advantage rather than a constraint when you can sell into markets with significantly higher price points.

Strategic Moves

Glass House was active beyond the financial results. The company announced a collaboration with UC Berkeley on state-funded cannabis crop yield research, appointed Alison Payne (Heineken USA's Chief Marketing Officer) to its board, established a Product Expansion Committee to support new product and business development, and announced a warrant redemption notice — all signals of a company building infrastructure for a much larger future.

The board-level additions are particularly telling. Bringing in a Heineken CMO suggests Glass House is thinking seriously about consumer branding and product diversification beyond bulk biomass — a necessary evolution if the company wants to capture value further up the supply chain.

The Bottom Line

Glass House's Q1 2026 is the kind of quarter that tests investor patience. Negative EBITDA, negative cash flow, compressed margins, declining year-over-year revenue — none of those headlines inspire confidence in isolation.

But the underlying thesis remains intact. Production volume is on track. The Greenhouse 2 expansion is complete. Cost per pound should decline materially through the year. The retail joint venture with Vireo adds scale and delivery infrastructure. DEA registration is filed. And the $95 cost target — which would produce industry-leading margins at current selling prices — remains achievable in the second half.

Glass House is building for a future where cannabis crosses borders — state and international. That future isn't here yet, and Q1's results reflect the cost of preparing for it. The question is whether the company can execute the cost improvements it's promising while California's market remains unforgiving.

Kazan has always bet that scale and cost advantage would eventually win. This is the quarter where that bet gets expensive. The next two quarters will determine whether it pays off.

📈 Dog Walkers

$MRMD ( ▲ 1.21% ) Reports Q1

MariMed isn't trying to be the biggest cannabis company in the room. It's trying to be the most efficient — and Q1 2026 suggests the strategy is working.

The multi-state operator reported Q1 revenue of $39.5 million, up 4.2% year-over-year from $37.9 million — a modest top-line improvement that masks more meaningful progress underneath. Non-GAAP adjusted EBITDA grew 44% to $3.6 million, with margins expanding from 7% to 9%. GAAP net loss narrowed to $3.8 million from $5.5 million, while non-GAAP net loss improved to $3.2 million from $3.9 million. The direction is clear: MariMed is generating more profit from each dollar of revenue, quarter after quarter.

The Brand Strategy

CEO Jon Levine framed the results around the company's "Expand the Brand" strategy — a deliberate effort to push MariMed's top-selling brands into broader distribution across both existing and new markets. That approach is showing up in the numbers, with growth driven by expanded wholesale distribution and retail performance rather than aggressive footprint expansion.

Levine highlighted that MariMed's products "maintained or grew their market-leading positions in the most popular categories across our wholesale markets" — a statement backed by what the company describes as operational excellence across innovation, manufacturing, and sell-through. In an industry where many operators are fighting pricing compression with volume, MariMed is leaning into brand strength and distribution discipline to drive incremental growth.

Gross margins held relatively steady at 39% GAAP and 40% non-GAAP, down just one percentage point year-over-year despite the pricing pressures affecting virtually every cannabis market in the country. Maintaining margins near 40% while growing revenue speaks to the quality of MariMed's cultivation and manufacturing operations.

Balance Sheet Cleanup

MariMed also took a meaningful step to strengthen its financial position during the quarter. In March, the company announced a Restructuring and Exchange Agreement with holders of its $14.725 million Series B Convertible Preferred Stock, eliminating a mandatory conversion date obligation that had been looming on February 26, 2026. The restructured arrangement replaces the near-term obligation with a combination of long-dated instruments, extending the weighted average maturity to 4.6 years and eliminating near-term refinancing risk.

That's the kind of quiet balance sheet management that doesn't generate headlines but materially improves a company's financial flexibility — particularly heading into a period where capital allocation decisions could be critical.

The Rescheduling Context

Levine positioned MariMed as "well-positioned to capitalize on this transformative period" following Schedule III rescheduling of medical cannabis. For a company focused on profitability improvement and disciplined execution, the elimination of 280E tax treatment on medical operations represents a direct boost to after-tax economics — additional margin expansion without requiring additional investment.

The Bottom Line

MariMed's Q1 won't make anyone's highlight reel for explosive growth. But 4% revenue growth, 44% EBITDA growth, narrowing losses, and a cleaned-up balance sheet tell the story of a company methodically building a more profitable business. In an industry that has burned billions chasing scale, MariMed's bet on brands, efficiency, and discipline is looking increasingly smart.

$TCNNF ( ▲ 2.59% ) Is Coming Back To The U.S.

The largest U.S. cannabis operator announced it will seek shareholder approval to redomicile from British Columbia, Canada to Delaware — a move that aligns the company's corporate structure with the reality that its entire business operates in the United States. A special shareholder meeting is scheduled for August 5, 2026, with a record date of June 8.

The move, structured as a plan of arrangement involving a continuance out of BC and concurrent domestication to Delaware, reflects a broader trend among U.S. cannabis companies that originally incorporated in Canada to access Canadian stock exchanges — the only major public markets that would list them. Now, with federal rescheduling advancing and the prospect of eventual U.S. exchange uplisting becoming more tangible, the Canadian corporate wrapper is increasingly more burden than benefit.

Delaware offers a well-established, business-friendly corporate legal framework that virtually every major U.S. public company utilizes — predictable case law, flexible governance structures, and a specialized Court of Chancery that handles corporate disputes with expertise unmatched by other jurisdictions. For a company of Trulieve's scale — 240 dispensaries, $287 million in quarterly revenue, over four million square feet of cultivation capacity — operating under Delaware corporate law is a natural fit.

Trulieve emphasized that the domestication is not expected to cause any material change in business or operations. The move is structural, not operational.

Completion requires Supreme Court of British Columbia approval, shareholder approval, authorization from BC's registrar, and other customary consents. The board retains discretion to abandon the arrangement even after shareholder approval.

Trulieve joins Jushi and other MSOs in signaling that the era of U.S. cannabis companies wearing Canadian corporate clothing is drawing to a close.

🗞️ The News

📺 Trade To Black

• Cannabis Sector Stabilization: Scott Grossman of Vindico Capital breaks down earnings season and whether improving investor sentiment has real substance behind it.

• MSO Deep Dive: The conversation covers Green Thumb Industries, Vireo Growth, and AYR Wellness, alongside broader themes of consolidation, distressed assets, private MSOs, Texas licensing, and whether cannabis eventually earns CPG-style valuations.

• Institutional Capital: Grossman weighs in on whether the industry could see another major institutional moment reminiscent of the Constellation Brands / Canopy Growth era.

• New Weekly Feature — Vantage Standard: The podcast launches a recurring segment exploring cannabinoids in regulated healthcare infrastructure, covering pharmaceutical-grade manufacturing, Medicare models, physician oversight, and how the industry intersects with formal U.S. healthcare systems.

• CBD Pilot Breakdown: Rusty Kuchta (Vantage CEO) and Dr. Paul Shields walk through how the federal CBD pilot program could evolve from early-stage framework into a full-scale healthcare model, with a step-by-step look at the process ahead.